A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma
The purpose of this study is to compare the effects, good or bad, of polatuzumab vedotin in combination with four other drugs, rituximab, cyclophosphamide, doxorubicin, and prednisone (when given together, referred to as R-CHP); compared with vincristine in combination with R-CHP (referred to as R-CHOP) on you and your lymphoma, to find out which is better.
Diffuse Large B-Cell Lymphoma (DLBCL)
Men and women ages 18-80 with previously untreated DLBCL
18 - 80
Healthy Volunteers Needed
Duration of Participation
You will be asked to take study treatment (R-CHP with polatuzumab vedotin and placebo instead of vincristine; or R-CHOP with placebo instead of polatuzumab vedotin) for approximately 18-24 weeks. The investigator will ask you to return to the clinic 4 to 8 weeks after your last dose of study treatment. Your total length of time in the study, including the screening, treatment, and follow-up periods, will be about 5.5 years.
Clinical Trials Information Line
Genentech, Inc., an affiliate of F. Hoffmann-La Roche Ltd.